NDAORALTABLET, EXTENDED RELEASE
Approved
May 2016
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
6/8 — Strong
JENTADUETO XR (linagliptin and metformin hydrochloride) by Boehringer Ingelheim is dipeptidyl peptidase 4 inhibitors [moa]. Approved for dipeptidyl peptidase 4 inhibitor [epc]. First approved in 2016.
Drug data last refreshed 4h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JENTADUETO XR is a fixed-dose combination tablet containing linagliptin (a DPP-4 inhibitor) and metformin hydrochloride (an extended-release formulation) for the treatment of type 2 diabetes mellitus. It works by inhibiting dipeptidyl peptidase-4, which increases incretin levels and reduces glucose production, while metformin decreases hepatic glucose synthesis and improves insulin sensitivity. The combination allows for once-daily dosing with improved glycemic control compared to monotherapy.
$30MPart D
PeakStable
11.3 years to LOEThe product is in peak revenue phase with modest Part D spending of $30M in 2023, suggesting a mature but stable market position with a focused commercial team.
Mechanism of Action
Dipeptidyl Peptidase 4 Inhibitors
Pharmacologic Class:
Dipeptidyl Peptidase 4 Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
JENTADUETO XR offers career opportunities in a stable, mature diabetes franchise within Boehringer Ingelheim's well-established DPP-4 portfolio. Roles focus on defending market share against GLP-1 competition, optimizing payer access, and managing the extended runway to generic entry through cost-containment and lifecycle management initiatives.
Brand Manager
Worked on JENTADUETO XR at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.